Clinical Trial Update: Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial assessing allogeneic double negative T cells (DNT-UHN-1) in high-risk acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allogeneic Double Negative T Cells (DNT-UHN-1)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED